Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human Development Index and outcomes in older critically ill patients: A European multicentre study.

Annals of intensive care·2026
Same author

Hypercalcemia in intensive care unit: pathophysiological mechanisms and clinical implications.

Intensive care medicine·2026
Same author

Implementation of the kidney protection strategy in critically ill patients with acute kidney injury - a multi-center prospective cohort study.

Critical care (London, England)·2026
Same author

Sex and 30-day mortality in elderly critically Ill adults: A frailty-adjusted multinational analysis with frequentist and bayesian estimates.

European journal of internal medicine·2026
Same author

Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management.

Critical care (London, England)·2026
Same author

Restrictive nutrition in shock: reassuring renal signals-but no proof of safety.

Intensive care medicine·2026
Same journal

Adsorption of Pathogens and Blockade of Sepsis Cascade.

Contributions to nephrology·2023
Same journal

Hemoadsorption: Research Agenda and Potential Future Applications.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Poisoning and Drug Overdose.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Burns.

Contributions to nephrology·2023
Same journal

Sequential Extracorporeal Therapy in Sepsis.

Contributions to nephrology·2023
Same journal

The Use of Adsorption in Extracorporeal Liver Support: The Double Plasma Molecular Adsorption System (DPMAS).

Contributions to nephrology·2023
See all related articles

Related Experiment Video

Updated: May 29, 2026

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

Why did dose trials fail?

Michael Joannidis1

  • 1Medical Intensive Care Unit, Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria.

Contributions to Nephrology
|September 17, 2011
PubMed
Summary
This summary is machine-generated.

Optimal intensity for renal replacement therapy in critically ill patients remains debated. Recent large trials suggest lower doses (20-25 ml/kg/h) or alternate-day dialysis may be sufficient, contrary to earlier findings.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Related Experiment Videos

Last Updated: May 29, 2026

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Intensive Care Unit Management

Background:

  • Determining optimal renal replacement therapy (RRT) intensity for critically ill patients has been a focus of research.
  • Several randomized controlled trials (RCTs) have investigated RRT dose, yielding conflicting results.
  • Earlier studies suggested higher RRT doses or daily dialysis improved survival.

Purpose of the Study:

  • To critically review and explain discrepant findings in RRT intensity trials.
  • To re-evaluate factors influencing RRT efficacy, including dose definition and patient characteristics.
  • To provide clarity on the optimal intensity for RRT in critically ill populations.

Main Methods:

  • Systematic review and critical appraisal of published randomized controlled trials on RRT intensity.
  • Analysis of methodological differences and patient populations across studies.
  • Re-examination of key concepts such as RRT dose, middle molecule clearance, and treatment timing.

Main Results:

  • Recent large-scale RCTs indicate that lower RRT intensities (20-25 ml/kg/h) or alternate-day schedules may be adequate.
  • Discrepancies in findings may stem from variations in dose definition, comparability, middle molecule clearance, and patient heterogeneity.
  • Earlier trials suggesting survival benefits with higher doses may not be generalizable.

Conclusions:

  • The optimal intensity for RRT in critically ill patients requires careful consideration of multiple factors beyond simple dose prescription.
  • Patient heterogeneity and methodological variations in trials significantly impact observed outcomes.
  • Further research should focus on standardizing RRT protocols and understanding individual patient responses to therapy.